WO2000061772A3 - Compositions and methods for generating an immune response utilizing alphavirus-based vector systems - Google Patents

Compositions and methods for generating an immune response utilizing alphavirus-based vector systems Download PDF

Info

Publication number
WO2000061772A3
WO2000061772A3 PCT/US2000/010722 US0010722W WO0061772A3 WO 2000061772 A3 WO2000061772 A3 WO 2000061772A3 US 0010722 W US0010722 W US 0010722W WO 0061772 A3 WO0061772 A3 WO 0061772A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
generating
compositions
vector systems
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/010722
Other languages
French (fr)
Other versions
WO2000061772A2 (en
Inventor
John M Polo
Thomas W Dubensky Jr
Ilya Frolov
Jason P Gardner
Gillis Otten
Susan Barnett
David A Driver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AT00923558T priority Critical patent/ATE463578T1/en
Priority to DE60044125T priority patent/DE60044125D1/en
Priority to CA2373300A priority patent/CA2373300C/en
Priority to DK00923558.1T priority patent/DK1175497T3/en
Priority to AU43660/00A priority patent/AU4366000A/en
Priority to EP00923558A priority patent/EP1175497B1/en
Priority to JP2000611695A priority patent/JP4637368B2/en
Publication of WO2000061772A2 publication Critical patent/WO2000061772A2/en
Publication of WO2000061772A3 publication Critical patent/WO2000061772A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods are provided for generating immune responses utilizing alphavirus-based vector systems.
PCT/US2000/010722 1999-04-14 2000-04-14 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems Ceased WO2000061772A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT00923558T ATE463578T1 (en) 1999-04-14 2000-04-14 COMPOSITIONS AND METHODS FOR TRIGGERING AN IMMUNE RESPONSE BASED ON ALPHAVIRUS VECTOR SYSTEMS
DE60044125T DE60044125D1 (en) 1999-04-14 2000-04-14 COMPOSITIONS AND METHODS FOR TRIGGING AN IMMUNE RESPONSE BASED ON ALPHAVIRUS VECTOR SYSTEMS
CA2373300A CA2373300C (en) 1999-04-14 2000-04-14 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DK00923558.1T DK1175497T3 (en) 1999-04-14 2000-04-14 Compositions and Methods for Generating an Immune Response by Utilizing Alpha Virus-Based Vector Systems
AU43660/00A AU4366000A (en) 1999-04-14 2000-04-14 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP00923558A EP1175497B1 (en) 1999-04-14 2000-04-14 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
JP2000611695A JP4637368B2 (en) 1999-04-14 2000-04-14 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12949899P 1999-04-14 1999-04-14
US60/129,498 1999-04-14
US14808699P 1999-08-09 1999-08-09
US60/148,086 1999-08-09
US19136300P 2000-03-22 2000-03-22
US60/191,363 2000-03-22

Publications (2)

Publication Number Publication Date
WO2000061772A2 WO2000061772A2 (en) 2000-10-19
WO2000061772A3 true WO2000061772A3 (en) 2001-02-08

Family

ID=27383889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010722 Ceased WO2000061772A2 (en) 1999-04-14 2000-04-14 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Country Status (9)

Country Link
US (1) US7771979B2 (en)
EP (2) EP1175497B1 (en)
JP (1) JP4637368B2 (en)
AT (1) ATE463578T1 (en)
AU (1) AU4366000A (en)
CA (2) CA2760534A1 (en)
DE (1) DE60044125D1 (en)
DK (1) DK1175497T3 (en)
WO (1) WO2000061772A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104853770A (en) * 2012-07-06 2015-08-19 诺华股份有限公司 Immunogenic compositions and uses thereof

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080982A2 (en) 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
AU2002303330B2 (en) 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
JP2006505280A (en) * 2002-11-07 2006-02-16 チャン・ルン−ジ Modified dendritic cells
NZ540657A (en) 2002-12-13 2006-09-29 Alphavax Inc High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine
US20040208848A1 (en) 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
CN1791678A (en) 2003-03-20 2006-06-21 阿尔法瓦克斯公司 Improved alphavirus replicons and helper constructs
DE602004021260D1 (en) 2003-07-11 2009-07-09 Alphavax Inc CYTOMEGALOVIRUS VACCINES BASED ON ALPHAVIRUS
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
EP1751289B1 (en) 2004-05-18 2009-01-14 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
BRPI0714495B8 (en) 2006-07-21 2021-05-25 California Inst Of Techn Deficient lentivirus for pseudotyped recombinant replication
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
EP2215231A4 (en) 2007-10-15 2010-12-01 Univ Queensland EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE
ES2455544T5 (en) 2009-07-24 2017-08-16 Immune Design Corp Pseudotyped lentivirus vectors with a sindbis virus envelope glycoprotein
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US9422529B2 (en) * 2010-12-22 2016-08-23 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
WO2012088473A1 (en) * 2010-12-22 2012-06-28 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
PT2831095T (en) 2012-03-30 2019-01-30 Immune Design Corp Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
RU2631002C2 (en) * 2012-12-05 2017-09-15 Тевакс Дженетикс Вэксин Ко., Лтд. Fusion proteins for application as immunogenic amplifying agents to induce antigen-specific t-cell response
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
EP4137150A1 (en) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
JP2019511255A (en) 2016-01-11 2019-04-25 バーンダリ，インク． Microneedle composition and method of using the same
EP3472193A4 (en) 2016-06-20 2020-01-08 The Board of Trustees of the Leland Stanford Junior University CIRCULAR RNA AND THEIR USE IN IMMUNO MODULATION
MX2019013259A (en) 2017-05-08 2020-01-13 Gritstone Oncology Inc Alphavirus neoantigen vectors.
CA3075532A1 (en) 2017-09-15 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Multiplex production and barcoding of genetically engineered cells
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY-DRUG CONJUGATE AND METHODS THEREOF
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
MX2021014525A (en) 2019-05-30 2022-03-17 Gritstone Bio Inc MODIFIED ADENOVIRUSES.
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
KR20230046313A (en) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 Multi-epitope vaccine cassette
US20250011787A1 (en) 2021-10-21 2025-01-09 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Retroelement-generated transcription factor decoys
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20250215422A1 (en) 2022-03-25 2025-07-03 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads RT-DNA Fidelity and Retron Genome Editing
CA3254576A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
US20250215458A1 (en) 2022-03-25 2025-07-03 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Production of reverse transcribed DNA (RT-DNA) using a retron reverse transcriptase from exogenous RNA
JP2025525569A (en) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038087A2 (en) * 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
WO1998036779A2 (en) * 1997-02-19 1998-08-27 University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5814482A (en) * 1993-09-15 1998-09-29 Dubensky, Jr.; Thomas W. Eukaryotic layered vector initiation systems

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
JP3022967B2 (en) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド Stereoregular polynucleotide binding polymer
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4927750A (en) 1986-04-09 1990-05-22 Jeanette Simpson Cell separation process
ES2061500T5 (en) 1986-06-17 2003-05-16 Chiron Corp DIAGNOSIS AND VACCINES OF DELTA HEPATITIS, ITS PREPARATION AND USE.
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) * 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (en) 1990-12-13 1990-12-13 Henrik Garoff DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
PT633929E (en) 1992-04-01 2004-07-30 Merix Bioscience Inc METHOD FOR PROLIFERATION (IN VITRO) OF DENTIFICAL CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENES
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5591579A (en) * 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US5532154A (en) * 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
DE4412794A1 (en) 1994-04-14 1995-12-14 Univ Ludwigs Albert Process for producing dendritic cells, cells thus obtained and containers for carrying out this process
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5646004A (en) 1994-08-31 1997-07-08 Activated Cell Therapy, Inc. Methods for enriching fetal cells from maternal body fluids
US5663051A (en) 1994-08-31 1997-09-02 Activated Cell Therapy, Inc. Separation apparatus and method
US5648219A (en) 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
JPH11504802A (en) * 1994-11-30 1999-05-11 カイロン コーポレイション Recombinant alphavirus vector
US5648248A (en) 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5811297A (en) 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
US5843712A (en) * 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
US5842723A (en) 1996-11-25 1998-12-01 Burex Automotive America, Inc. Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle
DE69942006D1 (en) * 1998-04-08 2010-03-25 Univ North Carolina CANCER VACCINATE CONTAINING ALPHAVIRUS REPLICON PARTICLES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814482A (en) * 1993-09-15 1998-09-29 Dubensky, Jr.; Thomas W. Eukaryotic layered vector initiation systems
WO1997038087A2 (en) * 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
WO1998036779A2 (en) * 1997-02-19 1998-08-27 University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENG XIONG ET AL: "SINDBIS VIRUS: AN EFFICIENT, BROAD HOST RANGE VECTOR FOR GENE EXPRESSION IN ANIMAL CELLS", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 243, no. 4895, 3 March 1989 (1989-03-03), pages 1188 - 1191, XP000023527, ISSN: 0036-8075 *
P BROSSART ET AL: "VIRUS-MEDIATED DELIVERY OF ANTIGENIC EPITOPES INTO DENDRITIC CELLS AS A MEANS TO INDUCE CTL", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 7, no. 158, 1 April 1997 (1997-04-01), pages 3270 - 3276, XP002075947, ISSN: 0022-1767 *
PUSHKO P ET AL: "Replicon-helper systems from attenuated Venezuelan Equine Encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo", VIROLOGY,US,ACADEMIC PRESS,ORLANDO, vol. 239, no. 2, 22 December 1997 (1997-12-22), pages 389 - 401, XP002123951, ISSN: 0042-6822 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104853770A (en) * 2012-07-06 2015-08-19 诺华股份有限公司 Immunogenic compositions and uses thereof

Also Published As

Publication number Publication date
EP2196472A3 (en) 2011-04-13
ATE463578T1 (en) 2010-04-15
US20080226598A1 (en) 2008-09-18
CA2373300A1 (en) 2000-10-19
JP2002541814A (en) 2002-12-10
EP1175497B1 (en) 2010-04-07
DK1175497T3 (en) 2010-05-31
US7771979B2 (en) 2010-08-10
JP4637368B2 (en) 2011-02-23
AU4366000A (en) 2000-11-14
WO2000061772A2 (en) 2000-10-19
DE60044125D1 (en) 2010-05-20
EP2196472A2 (en) 2010-06-16
CA2760534A1 (en) 2000-10-19
EP1175497A2 (en) 2002-01-30
CA2373300C (en) 2012-02-21

Similar Documents

Publication Publication Date Title
WO2000061772A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU2001249380A1 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU2001255610A1 (en) System and method related to generating and tracking an email campaign
AU5784100A (en) Method for enhancing an immune response
AU2001268627A1 (en) Compositions and methods for generating expression vectors through site-specificrecombination
AU2008243079A1 (en) Compositions and methods for generating an immune response
AU698457B2 (en) Nanoemulsion based on nonionic amphiphilic lipids and aminated silicones and uses
AU2001298063A1 (en) Methods and systems for generating business models
IL145891A0 (en) Methods and compositions for modulating an immune response
AU2002225512A1 (en) Immune system stimulation
AU2001266603A1 (en) System and method for returning merchandise
AU1349401A (en) Seismic isolation system
AU2002227130A1 (en) Enterprise test system having run time test object generation
AU2001238648A1 (en) Generalized text localization in images
AU6529900A (en) Novel cloning methods and vectors
AU7983198A (en) Improved methods for inducing an immune response
AU2002242085A1 (en) Methods and compositions useful for stimulating an immune response
AU2001290416A1 (en) Switching device system, components therefore and methods relating thereto
AU7968398A (en) Compositions, devices, kit and method for modulating immune response
AU1803401A (en) Methods and systems for generating tractograms
AU2001261628A1 (en) Cd28 synthebody for the modulation of immune responses
AU7474100A (en) Methods and compositions for reducing immune response
AU2001241996A1 (en) Rule based proximity and time based tracking system
AU7472600A (en) Satellite simulator
AU1597001A (en) Compositions and methods for modifying an immune response against tropomyosin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2373300

Country of ref document: CA

Ref country code: CA

Ref document number: 2373300

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 611695

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000923558

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000923558

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642